The prevention of perioperative anemia has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone tumor surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial, and intraoperative fluid administration strategy is an important confounding factor. The HEAL trial will assess whether ANH will improve postoperative hemoglobin levels when applying goal-directed fluid therapy in patients undergoing bone tumor surgery.
age 18 to 75 years;
undergoing elective bone tumor resection surgery;
preoperative hemoglobin ≥11 g/dL;
using a tourniquet;
palliative operation or minimally invasive surgery;
BMI<18.5 or >30Kg/m²;
international normalized ratio (INR) >1.5 or platelet count <100 × 10^9/L;